Metabolic Consequences of Gastrointestinal Surgery

• Status: Terminated
• Trial end date: 2019-03-11
• Target enrollment: 0
• Participant gender: All

Summary

Surgery on the gastrointestinal (GI) tract results in profound changes to the metabolic profile. This is well described, including the rapid resolution of diabetes seen after bariatric surgery. The underlying pathophysiology, and incidence in lean patients undergoing surgery for cancer, is somewhat less described. The investigators plan to assess the symptomatic and glycaemic profile, as well as causative pathways, for metabolic symptoms in patients after surgery on the GI tract. The investigators will use glucose tolerance tests, physiological challenges with somatostatin analogues and antibiotics, and assess tissue transcriptomic changes.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust
• Treatments: Rifaximin; Somatostatin

Criteria

Inclusion Criteria:

• Have undergone previous oesophageal or gastric resection

Exclusion Criteria:

• Age <18

• Recent history of untreated anaemia

• Donated blood in preceding 16 weeks

• Lack capacity to read and retain information about study

• Have a known allergy to interventional agent

• Have received a course of antibiotics in preceding two months

• Be on medication that interacts with intervention

• Have a history of C. difficile colitis